Ting D, Kaye S, Rauz S
medRxiv. 2025; .
PMID: 39974104
PMC: 11838979.
DOI: 10.1101/2025.01.18.25320772.
Bernstein I, Fernandez K, Stein J, Pershing S, Wang S
Taiwan J Ophthalmol. 2024; 14(3):352-359.
PMID: 39430348
PMC: 11488813.
DOI: 10.4103/tjo.TJO-D-24-00055.
Fevrier H, LaPrise A, Mbagwu M, Leng T, Torres A, Borkar D
Ophthalmol Sci. 2024; 4(5):100524.
PMID: 38881608
PMC: 11179401.
DOI: 10.1016/j.xops.2024.100524.
Colman B, Zhu Z, Qi Z, van der Walt A
Eye (Lond). 2024; 38(12):2448-2456.
PMID: 38844583
PMC: 11306594.
DOI: 10.1038/s41433-024-03160-8.
Davidson O, Rajesh A, Blazes M, Batchelor A, Lee A, Lee C
Clin Ophthalmol. 2024; 18:1257-1266.
PMID: 38741584
PMC: 11089303.
DOI: 10.2147/OPTH.S456252.
Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
Zarbin M, MacCumber M, Karcher H, Adiguzel E, Mayhook A, LaPrise A
Ophthalmol Ther. 2024; 13(5):1357-1368.
PMID: 38520643
PMC: 11039576.
DOI: 10.1007/s40123-024-00920-3.
[Frequency and distribution of the active agent of intravitreal injections in German centers 2015-2021-An oregis study].
Zimmermann J, Storp J, Dicke C, Leclaire M, Eter N
Ophthalmologie. 2024; 121(3):196-206.
PMID: 38315190
DOI: 10.1007/s00347-024-01986-x.
Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration: Up to 6-Year Analysis of the AAO IRIS® Registry.
Wykoff C, Garmo V, Tabano D, Menezes A, Kim E, Fevrier H
Ophthalmol Sci. 2024; 4(2):100421.
PMID: 38187126
PMC: 10767511.
DOI: 10.1016/j.xops.2023.100421.
Tube Versus Trabeculectomy IRIS Registry Study: 1-Year Secondary Treatment Outcomes.
Sun C, McSoley M, Lum F, Chang T, Gedde S, Vanner E
Am J Ophthalmol. 2023; 256:97-107.
PMID: 37625509
PMC: 11085044.
DOI: 10.1016/j.ajo.2023.08.011.
Incidence and Risk Factors for Retinal Detachment and Retinal Tear after Cataract Surgery: IRIS® Registry (Intelligent Research in Sight) Analysis.
Morano M, Khan M, Zhang Q, Halfpenny C, Wisner D, Sharpe J
Ophthalmol Sci. 2023; 3(4):100314.
PMID: 37274012
PMC: 10239011.
DOI: 10.1016/j.xops.2023.100314.
Causes of Childhood Blindness in the United States Using the IRIS® Registry (Intelligent Research in Sight).
Lim H, Pershing S, Moshfeghi D, Heo H, Haque M, Lambert S
Ophthalmology. 2023; 130(9):907-913.
PMID: 37037315
PMC: 10524509.
DOI: 10.1016/j.ophtha.2023.04.004.
[oregis-The German ophthalmological registry].
Storp J, Dicke C, Bohringer D, Schargus M, Eter N
Ophthalmologie. 2023; 120(7):717-725.
PMID: 36635592
DOI: 10.1007/s00347-022-01804-2.
Predictors of Long-term Ophthalmic Complications after Closed Globe Injuries Using the Intelligent Research in Sight (IRIS®) Registry.
Batchelor A, Lacy M, Hunt M, Lu R, Lee A, Lee C
Ophthalmol Sci. 2022; 3(1):100237.
PMID: 36561352
PMC: 9764252.
DOI: 10.1016/j.xops.2022.100237.
Prevalence of and Associated Factors for Eyelid Cancer in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Bas Z, Sharpe J, Yaghy A, Zhang Q, Shields C, Hyman L
Ophthalmol Sci. 2022; 3(1):100227.
PMID: 36439695
PMC: 9692036.
DOI: 10.1016/j.xops.2022.100227.
The American Academy of Ophthalmology IRIS Registry (Intelligent Research In Sight): current and future state of big data analytics.
Pershing S, Lum F
Curr Opin Ophthalmol. 2022; 33(5):394-398.
PMID: 35916568
PMC: 10849939.
DOI: 10.1097/ICU.0000000000000869.